Phase 3 clinical trial of ambroxol for Parkinson's confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Learn more
The lixisenatide trial
Another trial in the promising diabetes drug cohort for repurposing in Parkinson’s is evaluating the effect of lixisenatide on the progression of Parkinson’s. This trial is co-funded by Cure Parkinson’s and Van Andel Institute through the International Linked Clinical Trials programme. This study is being conducted in France…